Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 21.27 USD 0.85%
Market Cap: 1.5B USD
Have any thoughts about
Kiniksa Pharmaceuticals Ltd?
Write Note

Relative Value

The Relative Value of one KNSA stock under the Base Case scenario is 42.26 USD. Compared to the current market price of 21.27 USD, Kiniksa Pharmaceuticals Ltd is Undervalued by 50%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KNSA Relative Value
Base Case
42.26 USD
Undervaluation 50%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
53
vs Industry
64
Median 3Y
4.8
Median 5Y
4.5
Industry
7.7
Forward
3.5
vs History
vs Industry
1
Median 3Y
-4.4
Median 5Y
-5
Industry
22.7
Forward
-44.3
vs History
19
vs Industry
2
Median 3Y
20
Median 5Y
-5.7
Industry
21.6
vs History
19
vs Industry
2
Median 3Y
20
Median 5Y
-5.2
Industry
25.2
vs History
41
vs Industry
28
Median 3Y
3.2
Median 5Y
3.6
Industry
2.5
vs History
52
vs Industry
56
Median 3Y
4
Median 5Y
3.8
Industry
7.7
Forward
3
vs History
47
vs Industry
55
Median 3Y
4.5
Median 5Y
4.2
Industry
9
vs History
vs Industry
1
Median 3Y
-5.3
Median 5Y
-5.1
Industry
4.2
Forward
-44.8
vs History
vs Industry
1
Median 3Y
-5.2
Median 5Y
-4.9
Industry
4.1
Forward
-96.3
vs History
19
vs Industry
2
Median 3Y
15.1
Median 5Y
-4.2
Industry
5.7
vs History
19
vs Industry
2
Median 3Y
15.1
Median 5Y
-3.9
Industry
3.6
vs History
61
vs Industry
34
Median 3Y
3.9
Median 5Y
8.1
Industry
4.6

Multiples Across Competitors

KNSA Competitors Multiples
Kiniksa Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BM
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
1.5B USD 3.9 -167.2 -52.9 -48.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.4B USD 5.7 61.9 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 11 -243 24.2 25.5
US
Gilead Sciences Inc
NASDAQ:GILD
112.5B USD 4 892.3 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.3B USD 6 17.7 16.1 17.9
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
P/E Multiple
Earnings Growth
BM
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Average P/E: 208.4
Negative Multiple: -167.2
276%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -243
42%
US
Gilead Sciences Inc
NASDAQ:GILD
892.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
EV/EBITDA Multiple
EBITDA Growth
BM
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Average EV/EBITDA: 17.2
Negative Multiple: -52.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
EV/EBIT Multiple
EBIT Growth
BM
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Average EV/EBIT: 22.6
Negative Multiple: -48.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A

See Also

Discover More
Back to Top